Patient Materials Adherence
Client situation
Bayer approached us, as the company wished to improve its patient materials further for its product Eylea® which is approved for the treatment of age-related macular degeneration. A particular emphasize was supposed to be put on the key topics patient-oriented language and adherence.
Our solution
We advised Bayer in detail on the topics of patient-oriented language and adherence and subsequently designed a variety of new patient materials, which were further optimized in the sense of a co-creation process with the involvement of patients.
Client benefits
The materials we created were very well received by patients and make an important contribution to improve adherence in the use of Eylea®.